MarketCap
Facebook
X
Telegram
Cardiovascular Systems Deferred Revenue | CSII
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.11 M | 2.4 M | 1.87 M | 1.76 M | 1.24 M | - | - | - | 59 K | 156 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.4 M | 59 K | 1.37 M |
Quarterly Deferred Revenue Cardiovascular Systems
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 525 K | 694 K | 525 K | 2.81 M | 2.72 M | 2.49 M | 2.72 M | 2.49 M | 2.26 M | 2.4 M | 2.08 M | 2.09 M | 1.66 M | 1.71 M | 1.66 M | 1.61 M | 1.52 M | 1.25 M | 1.52 M | 1.55 M | 1.1 M | 1.24 M | 1.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.81 M | 525 K | 1.73 M |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
6.64 M | - | - | $ 162 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | USA |
 |
Eargo
EAR
|
311 K | - | - | $ 10.2 M | USA |
 |
LENSAR
LNSR
|
2.6 M | $ 5.6 | -2.78 % | $ 67 M | USA |
 |
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | USA |
 |
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | USA |
 |
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | USA |
 |
Outset Medical
OM
|
13.8 M | $ 4.04 | -4.49 % | $ 61.5 K | USA |
 |
AxoGen
AXGN
|
14 K | $ 39.49 | -0.6 % | $ 1.82 B | USA |
 |
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | USA |
 |
Insulet Corporation
PODD
|
14 M | $ 163.26 | 3.08 % | $ 11.5 B | USA |
 |
Quanterix Corporation
QTRX
|
20.7 M | $ 3.67 | -6.38 % | $ 156 M | USA |
 |
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | USA |
 |
Bruker Corporation
BRKR
|
441 M | $ 60.45 | -2.74 % | $ 9.18 B | USA |
 |
Sintx Technologies
SINT
|
4.72 K | $ 1.42 | -6.58 % | $ 3.94 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | USA |
 |
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | USA |
 |
TransMedics Group
TMDX
|
2.9 M | $ 72.26 | 1.59 % | $ 2.46 B | USA |
 |
IRIDEX Corporation
IRIX
|
2.16 M | $ 0.89 | -3.38 % | $ 15.1 M | USA |
 |
Tandem Diabetes Care
TNDM
|
9.53 M | $ 17.12 | 1.3 % | $ 1.16 B | USA |
 |
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
1.67 M | $ 14.12 | -2.55 % | $ 400 M | USA |
 |
Viemed Healthcare
VMD
|
7.52 M | $ 11.77 | 0.86 % | $ 458 M | USA |
 |
Beyond Air
XAIR
|
777 K | $ 5.16 | -5.67 % | $ 42.8 B | USA |
 |
Invacare Corporation
IVC
|
2.28 M | - | - | $ 24.7 M | USA |
 |
Cytosorbents Corporation
CTSO
|
182 K | $ 0.36 | -0.39 % | $ 22.4 M | USA |
 |
NanoVibronix
NAOV
|
175 K | - | - | $ 1.08 M | USA |
 |
Natus Medical Incorporated
NTUS
|
25.1 M | - | 1.94 % | $ 1.05 B | USA |
 |
Inogen
INGN
|
5.48 M | $ 6.15 | -2.69 % | $ 164 M | USA |